Bionano Genomics, Inc.

BNGO - Financial Snapshot

Metrics for BNGO

Price $1.59
Shares Outstanding 9.68M
Net Current Assets / Share $2.02
netCurrentAssetsPerShare = (Current Assets - Total Liabilities) / Shares Outstanding
Net Tangible Assets / Share $4.56
netTangibleAssetsPerShare = (Total Assets - Intangibles - Total Liabilities) / Shares Outstanding
Max Earning Power / Share $-5.64
maxEarningPowerPerShare = (EBITDA / EP_MULTIPLIER) / Shares Outstanding
Adjusted Earning Power $-8.37
adjustedEarningPower = (Net Income / EP_MULTIPLIER) / Shares Outstanding
Non-Cash Charges to Market Cap 16.49%
nonCashChargeToMKTCAP = Non-Cash Charges / Market Capitalization
Ave Max Earning Power (5Y) $0.00
Ave Max Earning Power (5Q Annualized) $0.00
Ave Max Earning Power Delta (5Q Ann - 5Y) $0.00
Net Cash / Share $0
cashValuePerShare = (Cash + Short Term Investments - Total Liabilities) / Shares Outstanding
Data as of: Price 12-18-25 16:00 ET, Balance Sheet 2025-09-30, Income Statement 2025-09-30, Cash Flow 2025-09-30

Indicators

Dividend indicators Value Date
Pays Dividend No 12-19-2025
Income indicators Value Date
EBITDA Positive No 12-19-2025
Net Income Positive No 12-19-2025
Avg CA Burn (Annual %) -113.42% 12-19-2025
Avg CA Burn (Quarterly %) 0.10% 12-19-2025

Shares Outstanding Changes

Date Shares Outstanding Delta
2025-09-25 9,680,265 +4,925,000
2025-09-22 4,755,265 +74,265
2025-08-19 4,681,000 +1,317,000

Bionano Genomics, Inc., together with its subsidiaries, provides genome analysis solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. It also provides Saphyr and Stratys systems, which are sample-to-result solutions for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr and Stratys instruments, which are single-molecule imagers; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight DNA; and Ionic purification system, which isolates and purifies nucleic acid molecules. In addition, the company offers Saphyr, Stratys, and Bionano compute servers; and VIA software, which offers one solution for analysis and interpretation of genomic data from microarray and sequencing data for cytogenetics and molecular genetics. Further, it provides testing and laboratory services comprising FirstStepDx PLUS, a chromosomal microarray for identifying an underlying genetic cause in individuals with autism spectrum disorder, developmental delay, and intellectual disability; Fragile X syndrome (FXS) testing services; NextStepDx PLUS, a exome sequencing test to identify genetic variants that are associated with disorders of childhood development; OGM-Dx HemeOne testing; OGM-Dx FSHD, a test for individuals suspected of having FSHD type 1; and OGM-Dx Postnatal Whole Genome SV and OGM-Dx Prenatal Whole Genome SV for comprehensive testing. Bionano Genomics, Inc. was founded in 2003 and is headquartered in San Diego, California.